Moderna Inc

MRNA is in a Stage 3 distribution phase after a clear support failure, with price making lower highs and breaking key levels on expanding volume. The drop below the declining 9- and 21-day EMAs and follow-through selling reinforces a medium-term bearish bias. Short-term conditions favor immediate selling as price remains below EMAs and is approaching the 50-day moving average support amid oversold readings. While the long-term uptrend (rising 50- and 200-day DMAs) remains intact, it is secondary to the prevailing distribution dynamics. We will Sell Now into this continued weakness.

• ↑Q1’26 revenue $400M (+300% YoY) led by partnerships and intl sales
• ↑$7.5B cash & investments secures liquidity for R&D and ops
• ↓Q1’26 net loss $1.3B driven by litigation settlements and high opex